🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with had a fibroscan and do not understand my results - help? Page 2

Has anyone dealt with had a fibroscan and do not understand my results - help?

pat_auckland Fri, Apr 5, 2024 at 7:32 AM 42 replies 2,471 viewsPage 2 of 9
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Apr 5, 2024 at 9:05 AM#6
PharmD_Rodriguez said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 333 dB/m (moderate steatosis) and stiffness 8.8 kPa (possible fibrosis). Diagnosed with NAFLD.

After 13 months: CAP dropped to 226 dB/m (minimal steatosis) and stiffness normalized to 5.3999999999999995 kPa. Hepatologist says the liver is essentially healing itself as the metabolic stress resolves.

GLP-1 agonists may become first-line NASH therapy. The Phase 3 data on semaglutide for NASH is very promising.

Last edited: Apr 5, 2024 at 3:05 PM
45 15JakeSmashed95, NauseaFreeNow, SteveThurs and 42 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Apr 5, 2024 at 9:41 AM#7
pat_auckland said:
ALT was mildly raised at baseline, normalised at month five, and I now have no idea whether anything happened to the fibrosis that actually matters.

ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase 3 ATTAIN trial. NASH resolution was achieved in ~60% of patients[1].

This is relevant to liver and MASH because survodutide's glucagon agonism specifically targets hepatic lipid metabolism — making it potentially the best-in-class agent for NASH/MAFLD comorbid with obesity.

References:
[1] Sanyal AJ, et al. N Engl J Med. 2024.
44 14stefan_berlin, Dr.EM_Chicago, pete_RVA and 41 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Apr 5, 2024 at 10:17 AM#8
amsterdam_pete said:
Liver imaging follow-up for liver and MASH: FibroScan at baseline showed CAP score 333 dB/m (moderate steatosis) and stiffness 8.8 kPa (possible…

Adding the part of the answer the thread has not reached. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

That is the short version; the long version is somebody else's post.

43 13SteveThurs, B12Beth, RickReta_CO and 40 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
emma_london
Member
312
1,456
Oct 2024
London, UK
Apr 5, 2024 at 10:53 AM#9

A narrower follow-up, since the general answer is now clear:

Was that from a primary source or from a summary of one?

42 12JessicaM_2024, TomFromTexas, mike.trainer_LA and 39 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Apr 5, 2024 at 1:46 PM#10

OP back with an update, since a thread like this is useless without one.

Coming back a few months on. It held. Nothing dramatic to report, which is the report.

Last edited: Apr 5, 2024 at 5:46 PM
24 22dan_philly, MeganSA_TX, LarryQC_SD and 21 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register